Europe Approves Empagliflozin for Chronic Kidney Disease

The SGLT2 inhibitor empagliflozin (Jardiance) was approved by European regulators for treating adults with chronic kidney disease. The FDA is reviewing a new drug application for this indication.
Medscape Medical News

source https://www.medscape.com/viewarticle/994859?src=rss

Comments

Popular posts from this blog

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?